Sex differences in pharmacokinetics of cilostazol in rats

Xenobiotica

Volumn 41, Issue 10, 2011, Pages 903-913

  Kamada, Naoki ^a,b   Yamada, Keigo ^b   Odomi, Masaaki ^b   Mukai, Tadashi ^b   Nishibayashi, Toru ^b   Ogawara, Ken Ichi ^a   Kimura, Toshikiro ^a   Higaki, Kazutaka ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Bioavailability; first pass metabolism; gender; hepatic clearance; intestinal absorption; total body clearance

Indexed keywords

3,4 DIHYDRO 6 [4 [1 (4 HYDROXYCYCLOHEXYL) 1 H TETRAZOL 5 YL] BUTOXY] 2(1H)QUINOLINONE; 3,4 DIHYDRO 6 [4 [1 (4 HYDROXYCYCLOHEXYL) 1H TETRAZOL 5 YL BUTOXY] 2(1H) QUINOLINONE; 6 [4 (1 CYCLOHEXYL 1H TETRAZOL 5 YL)BUTOXY] 3,4 DIHYDRO 4 HYDROXYL 2(1H) QUINOLINONE; CILOSTAZOL; CYTOCHROME P450 2C11; CYTOCHROME P450 3A2; DEHYDROCILOSTAZOL; DRUG METABOLITE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FECES LEVEL; DRUG METABOLISM; FEMALE; FIRST PASS EFFECT; IN VITRO STUDY; IN VIVO STUDY; INTESTINE ABSORPTION; LIVER CLEARANCE; LIVER MICROSOME METABOLISM; LIVER PERFUSION; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; RAT; SEX DIFFERENCE; SPECIES DIFFERENCE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP3A; FEMALE; INTESTINE, SMALL; LIVER; MALE; MEMBRANE PROTEINS; MICROSOMES, LIVER; RATS; RATS, WISTAR; SEX CHARACTERISTICS; STEROID 16-ALPHA-HYDROXYLASE; TETRAZOLES;

RATTUS;

EID: 80052890662     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2011.590242     Document Type: Article

References (43)

1. Abbas R, Chow CP, Browder NJ, Thacker D, Bramer SL, Fu CJ, Forbes W, Odomi M, Flockhart DA. (2000).In vitro metabolism and interaction of cilostazol with human hepatic cytochrome P450 isoforms. Hum Exp Toxicol 19:178-184. (Pubitemid 30411779)
2. Aiba T, Yoshinaga M, Ishida K, Takehara Y, Hashimoto Y. (2005).Intestinal expression and metabolic activity of the CYP3A subfamily in female rats. Biol Pharm Bull 28:311-315. (Pubitemid 40880015)
3. Akiyama H, Kudo S, Shimizu T. (1985a).The absorption, distribution and excretion of a new antithrombotic and vasodilating agent, cilostazol, in rat, rabbit, dog and man. Arzneimittelforschung 35:1124-1132. (Pubitemid 15030825)
4. Akiyama H, Kudo S, Shimizu T. (1985b).The metabolism of a new antithrombotic and vasodilating agent, cilostazol, in rat, dog and man. Arzneimittelforschung 35:1133-1140. (Pubitemid 15030826)
5. Amidon GL, Lennernäs H, Shah VP, Crison JR. (1995).A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413-420.
6. Artursson P, Palm K, Luthman K. (2001).Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 46:27-43.
7. Asaoka Y, Sakai H, Sasaki J, Goryo M, Yanai T, Masegi T, Okada K. (2010).Changes in the gene expression and enzyme activity of hepatic cytochrome P450 in juvenile Sprague-Dawley rats. J Vet Med Sci 72:471-479.
8. Bramer SL, Forbes WP, Mallikaarjun S. (1999).Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease. Clin Pharmacokinet 37 Suppl 2:1-11. (Pubitemid 30171182)
9. Brandstetter Y, Kaplanski J, Leibson V, Ben-Zvi Z. (1986).The effects of estrus cycle on drug metabolism in the rat. Eur J Drug Metab Pharmacokinet 11:251-254. (Pubitemid 17045411)
10. Cao X, Gibbs ST, Fang L, Miller HA, Landowski CP, Shin HC, Lennernas H, Zhong Y, Amidon GL, Yu LX, Sun D. (2006).Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm Res 23:1675-1686. (Pubitemid 44200529)
11. Chan S, Edwards SR, Wyse BD, Smith MT. (2008).Sex differences in the pharmacokinetics, oxidative metabolism and oral bioavailability of oxycodone in the Sprague-Dawley rat. Clin Exp Pharmacol Physiol 35:295-302. (Pubitemid 351257877)
12. Chiou WL, Barve A. (1998).Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats. Pharm Res 15:1792-1795. (Pubitemid 28524594)
13. Chong S, Dando SA, Soucek KM, Morrison RA. (1996).In vitro permeability through caco-2 cells is not quantitatively predictive of in vivo absorption for peptide-like drugs absorbed via the dipeptide transporter system. Pharm Res 13:120-123. (Pubitemid 26076307)
14. Davies B, Morris T. (1993).Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095. (Pubitemid 23211439)
15. Eeckhoudt SL, Horsmans Y, Verbeeck RK. (2002).Differential induction of midazolam metabolism in the small intestine and liver by oral and intravenous dexamethasone pretreatment in rat. Xenobiotica 32:975-984. (Pubitemid 35347005)
16. Fujita Y, Yamada Y, Kusama M, Yamauchi T, Kamon J, Kadowaki T, Iga T. (2003).Sex differences in the pharmacokinetics of pioglitazone in rats. Comp Biochem Physiol C Toxicol Pharmacol 136:85-94. (Pubitemid 38352657)
17. Galetin A, Hinton LK, Burt H, Obach RS, Houston JB. (2007).Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugs. Curr Drug Metab 8:685-693. (Pubitemid 47591312)
18. Hanada K, Fujisawa R, Kataoka R, Nakamura S, Ogata H. (2001).Sexrelated differences in the renal disposition of the acidic metabolite of clentiazem in rat. Xenobiotica 31:725-731. (Pubitemid 33001096)
19. Higaki K, Ishii M, Esumi H, Kanayama M, Ogawara KI, Kimura T. (2003).Pharmacokinetic analysis of factors determining elimination pathways for sulfate and glucuronide metabolites of xenobiotics II: Studies with isolated perfused rat liver. Xenobiotica 33:1097-1108. (Pubitemid 37500167)
20. Higaki K, Nakano M. (1992).Stereoselective disposition of S-8666, a novel uricosuric antihypertensive diuretic, and its N-monodemethylated metabolite in a perfused rat liver preparation. Effect of protein binding on the kinetics of S-8666. Drug Metab Dispos 20:350-355.
21. Higaki K, Sone M, Ogawara K, Kimura T. (2004).Regulation of drug absorption from small intestine by enteric nervous system I: a poorly absorbable drug via passive diffusion. Drug Metab Pharmacokinet 19:198-205.
22. Hiratsuka M, Hinai Y, Sasaki T, Konno Y, Imagawa K, Ishikawa M, Mizugaki M. (2007).Characterization of human cytochrome p450 enzymes involved in the metabolism of cilostazol. Drug Metab Dispos 35:1730-1732. (Pubitemid 47481597)
23. Imaoka S, Yamada T, Hiroi T, Hayashi K, Sakaki T, Yabusaki Y, Funae Y. (1996).Multiple forms of human P450 expressed in Saccharomyces cerevisiae. Systematic characterization and comparison with those of the rat. Biochem Pharmacol 51:1041-1050.
24. Janssen FW, Young EM, Ruelius HW. (1976).Effect of sex hormones on the disposition in rats of 1-aminocyclohexane carboxylic acid, a metabolite of semisynthetic penicillin. Drug Metab Dispos 4:540-546. (Pubitemid 8002365)
25. Jinno J, Kamada N, Miyake M, Yamada K, Mukai T, Odomi M, Toguchi H, Liversidge GG, Higaki K, Kimura T. (2006).Effect of particle size reduction on dissolution and oral absorption of a poorly watersoluble drug, cilostazol, in beagle dogs. J Control Release 111:56-64. (Pubitemid 43289995)
26. Kato R. (1974).Sex-related differences in drug metabolism. Drug Metab Rev 3:1-32.
27. Kato R, Yamazoe Y. (1992).Sex-specific cytochrome P450 as a cause of sex- and species-related differences in drug toxicity. Toxicol Lett 64-65 Spec No:661-667.
28. Kato Y, Kuge K, Kusuhara H, Meier PJ, Sugiyama Y. (2002).Gender difference in the urinary excretion of organic anions in rats. J Pharmacol Exp Ther 302:483-489. (Pubitemid 34787210)
29. Komura H, Iwaki M. (2008).Species differences in in vitro and in vivo small intestinal metabolism of CYP3A substrates. J Pharm Sci 97:1775-1800.
30. Kotegawa T, Laurijssens BE, Von Moltke LL, Cotreau MM, Perloff MD, Venkatakrishnan K, Warrington JS, Granda BW, Harmatz JS, Greenblatt DJ. (2002).In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat. J Pharmacol Exp Ther 302:1228-1237. (Pubitemid 34920247)
31. Kvetina J, Guaitani A. (1969).A versatile method for the in vitro perfusion of isolated organs of rats and mice with particular reference to liver. Pharmacology 2:65-81.
32. Matsubara T, Kim HJ, Miyata M, Shimada M, Nagata K, Yamazoe Y. (2004).Isolation and characterization of a new major intestinal CYP3A form, CYP3A62, in the rat. J Pharmacol Exp Ther 309:1282-1290. (Pubitemid 38669720)
33. Mihara K, Matsumura M, Yoshioka E, Hanada K, Nakasa H, Ohmori S, Kitada M, Ogata H. (2001).Intestinal first-pass metabolism of eperisone in the rat. Pharm Res 18:1131-1137. (Pubitemid 32900398)
34. Mortimore GE. (1961).Effect of insulin on potassium transfer in isolated rat liver. Am J Physiol 200:1315-1319.
35. Mugford CA, Kedderis GL. (1998).Sex-dependent metabolism of xenobiotics. Drug Metab Rev 30:441-498. (Pubitemid 28384436)
36. Sato M, Suzaka H, Miyazaki H. (2000).Sex-related differences in urinary excretion of egualen sodium in rats. Drug Metab Dispos 28:21-27. (Pubitemid 30027507)
37. Sun D, Yu LX, Hussain MA, Wall DA, Smith RL, Amidon GL. (2004).In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome. Curr Opin Drug Discov Devel 7:75-85. (Pubitemid 44111916)
38. Tanaka Y, Deguchi Y, Ishii I, Terai T. (1991).Sex differences in excretion of zenarestat in rat. Xenobiotica 21:1119-1125.
39. Terashita S, Sawamoto T, Deguchi S, Tokuma Y, Hata T. (1995).Sexdependent and independent renal excretion of nilvadipine metabolites in rat: evidence for a sex-dependent active secretion in kidney. Xenobiotica 25:37-47.
40. Toyobuku H, Tamai I, Ueno K, Tsuji A. (2003).Limited influence of P-glycoprotein on small-intestinal absorption of cilostazol, a high absorptive permeability drug. J Pharm Sci 92:2249-2259. (Pubitemid 37356698)
41. Waxman DJ, Holloway MG. (2009).Sex differences in the expression of hepatic drug metabolizing enzymes. Mol Pharmacol 76:215-228.
42. Yang SH, Yang KH, Lee MG. (2008).Gender differences in ondansetron pharmacokinetics in rats. Biopharm Drug Dispos 29:406-413.
43. Yoo HD, Cho HY, Lee YB. (2010).Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1. Br J Clin Pharmacol 69:27-37.